Minimal Change Disease Is Associated With Endothelial Glycocalyx Degradation and Endothelial Activation
Overview
Authors
Affiliations
Introduction: Minimal change disease (MCD) is considered a podocyte disorder triggered by unknown circulating factors. Here, we hypothesized that the endothelial cell (EC) is also involved in MCD.
Methods: We studied 45 children with idiopathic nephrotic syndrome (44 had steroid sensitive nephrotic syndrome [SSNS], and 12 had biopsy-proven MCD), 21 adults with MCD, and 38 healthy controls (30 children, 8 adults). In circulation, we measured products of endothelial glycocalyx (EG) degradation (syndecan-1, heparan sulfate [HS] fragments), HS proteoglycan cleaving enzymes (matrix metalloprotease-2 [MMP-2], heparanase activity), and markers of endothelial activation (von Willebrand factor [vWF], thrombomodulin) by enzyme-linked immunosorbent assay (ELISA) and mass spectrometry. In human kidney tissue, we assessed glomerular EC (GEnC) activation by immunofluorescence of caveolin-1 ( 11 MCD, 5 controls). , we cultured immortalized human GEnC with sera from control subjects and patients with MCD/SSNS sera in relapse ( 5 per group) and performed Western blotting of thrombomodulin of cell lysates as surrogate marker of endothelial activation.
Results: In circulation, median concentrations of all endothelial markers were higher in patients with active disease compared with controls and remained high in some patients during remission. In the MCD glomerulus, caveolin-1 expression was higher, in an endothelial-specific pattern, compared with controls. In cultured human GEnC, sera from children with MCD/SSNS in relapse increased thrombomodulin expression compared with control sera.
Conclusion: Our data show that alterations involving the systemic and glomerular endothelium are nearly universal in patients with MCD and SSNS, and that GEnC can be directly activated by circulating factors present in the MCD/SSNS sera during relapse.
Tsikouras P, Nikolettos K, Kotanidou S, Kritsotaki N, Oikonomou E, Bothou A J Clin Med. 2025; 14(3).
PMID: 39941563 PMC: 11818630. DOI: 10.3390/jcm14030892.
Cricri G, Gobbini A, Bruno S, Bellucci L, Tassinari S, Caicci F Sci Rep. 2024; 14(1):25765.
PMID: 39468184 PMC: 11519447. DOI: 10.1038/s41598-024-76727-w.
Woo H, Park M, Song T Sci Rep. 2024; 14(1):25376.
PMID: 39455616 PMC: 11511921. DOI: 10.1038/s41598-024-75384-3.
Wang B, Jiang C, Qu Y, Wang J, Yan C, Zhang X Lipids Health Dis. 2024; 23(1):312.
PMID: 39334373 PMC: 11429454. DOI: 10.1186/s12944-024-02288-6.
Association of serum syndecan-1 concentrations with albuminuria in type 2 diabetes.
Kakutani Y, Morioka T, Yamazaki Y, Ochi A, Fukumoto S, Shoji T Diab Vasc Dis Res. 2024; 21(4):14791641241278362.
PMID: 39155787 PMC: 11331450. DOI: 10.1177/14791641241278362.